⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387687 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL3092750 | 0.74 | MAOB (0.34) | — | |
| SCHEMBL5729904 | 0.72 | TSHR (0.32) | — | |
| SCHEMBL10764522 | 0.72 | — | — | |
| SCHEMBL7704602 | 0.72 | ALDH1A1 (0.30) | — | |
| SCHEMBL10700263 | 0.69 | — | — | |
| SCHEMBL353354 | 0.67 | ALDH1A1 (0.36) | — | |
| SCHEMBL10701950 | 0.67 | — | — | |
| SCHEMBL35603 | 0.65 | — | — | |
| SCHEMBL1720228 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332515-B2 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070123528-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | disclosed |
| US-7166636-B2 | Type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, or hyperglucagonemia; methyl (S)-5-{1-[(5-chloro-1H-indol-2-ylcarbonyl)amino]-2-phenylethyl}oxazole-4-carboxylate; amidation by reacting the 2-carboxyindole and a 1,2-diphenylethylamine | ASTRAZENECA AB (SE) | 2007-01-23 | — | — | US | disclosed |
| EP-1483271-B1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-7138415-B2 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-21 | — | — | US | disclosed |
| US-7122567-B2 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20050131052-A1 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050130963-A1 | Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050107362-A1 | Indolamid derivatives which possess glycogenphosphorylase inhibitory activity | ASTRA ZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1492788-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| EP-1483240-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1483271-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074517-A1 | INDOLE-AMID DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074531-A1 | HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074484-A1 | INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |